一、临床药理学与治疗学 (2025年第118卷第6期)
Clinical Pharmacology & Therapeutics 
December 2025 - Volume 118 - Issue 6（2025年12月第118卷第6期）
https://ascpt.onlinelibrary.wiley.com/toc/15326535/2025/118/6

Editorial（社论）
1.历史是什么？ 是未来的过去回响，亦是过去的未来映射
What is History? An Echo of the Past in the Future; A Reflex From the Future on the Past
Kathleen M. Giacomini*
2.临床药理学创新： 如何塑造药物研发与应用的未来证据体系
Innovations in Clinical Pharmacology: Shaping the Future of Evidence Generation in Research, Development, and Utilization of Medicines
Karthik Venkatakrishnan*
3.成长的季节： 回首《CPT》期刊主编培训计划的点滴
Seasons of Growth: Reflections on the CPT Editor-in-Training Program
Matthijs W. van Hoogdalem*
Perspective（观点）
4.加速日本新药审批： 来自药品医疗器械审评机构的见解
Expediting Drug Development in Japan: A PMDA Perspective
Yoichi Kohno, Yoshiaki Uyama*
5.新兴工具与技术： 如何在药物研发中纳入“微生物组”考量
Emerging Tools and Technologies for Microbiome-Aware Drug Development
Henry J. Haiser*
6.新方法学来了： 临床药理学家需要做好哪些准备？
New Approach Methodologies: What Clinical Pharmacologists Should Prepare For
Yanguang Cao*
7.定量蛋白质组学的潜力： 为新型研究方法学提供“资格认证”
Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies
Bhagwat Prasad*
White Paper（白皮书）
8.儿童罕见病药物研发的创新与最佳实践： 基于模型的研发视角
Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model-Informed Drug Development Perspective
Rajesh Krishna*
9.用药物基因组学革新药物警戒： 迈向个性化风险管理
Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management
Claire Spahn*
Review（综述）
State of the Art Review（前沿综述）
10.mRNA疗法与疫苗的临床与定量药理学考量： 弥合转化研究与平台决策间的鸿沟
Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making
Linh M. Van*
11.临床药理学创新的历史与演进
History and Evolution of Innovations in Clinical Pharmacology
Lawrence J. Lesko*
12.模型引导的药物研发在mRNA-LNP疗法中的应用与机遇
Model-Informed Drug Development Applications and Opportunities in mRNA-LNP Therapeutics
Jiawei Zhou*
13.HIV药理学数据仓库： 为临床与临床前药代动力学研究树立数据共享新标准
HIV Pharmacology Data Repository: Setting the New Information-Sharing Standard for Clinical and Preclinical Pharmacokinetic Studies
Lauren A.R. Tompkins, Mackenzie L. Cottrell*
14.包含实用元素的临床试验： 用例回顾与真实世界数据应用
Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real-World Data Utilization
Le Su, Mehmet Burcu*
15.药物微生物组学
Pharmacomicrobiomics
Naomi Gronich*
16.加速MASH药物发现与开发的定量方法
Quantitative Approaches to Accelerate MASH Drug Discovery and Development
Yasmeen Abouelhassan, Maria E. Trujillo*
17.从创新到安全有效药物的快速通道
A Fast Path from Innovation to Safe and Effective Medicines
Peter Arlett, Steffen Thirstrup*
Systematic Review（系统综述）
18.日本新药与再生医疗产品审批中真实世界数据与证据应用的演变趋势（基于6年数据分析）
Evolving Real-World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6-Year Trend
Suguru Okami*
19.非洲地区双药抗病毒疗法的高病毒抑制率与良好特性： 当前证据的系统性回顾
High Virologic Suppression and Favorable Profiles of Two-Drug Antiretroviral Regimens in Africa: A Systematic Review of Current Evidence
Paul Achile Akpa, AbdulMuminu Isah*
Practice Guideline（实践指南）
20.临床药物遗传学实施联盟指南： NAT2 基因型与肼屈嗪治疗方案
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
Michael T. Eadon*
Research（研究）
Brief Report（简报）
21.利用无创肠道采样装置，解析柳氮磺吡啶与5-ASA的时空药代动力学特征
Spatiotemporal Characterization of Sulfasalazine and 5-ASA Pharmacokinetics Using a Noninvasive Intestinal Sampling Device
Jingwei Cai*
Article（文章）
22.利用德国真实世界数据为单臂试验构建外部对照臂的评估研究
Supplementing Single-Arm Trials with External Control Arms—Evaluation of German Real-World Data
Martin Russek, Britta Haenisch*
23.siRNA药物JNJ-73763989在健康受试者与慢性乙肝患者中的群体药代动力学研究
Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis B
Tetsuro Ogawa, Huybrecht T’jollyn*
24.重新定位药物： 多组学与多模态数据分析揭示醋丁洛尔治疗骨质疏松症的潜力
Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi-Omics and Multi-Modal Data Analysis
Dan-Yang Liu, Hong-Wen Deng*
25.“微生物组知情”给药： 探索肠道菌群如何影响霉酚酸酯的肠肝循环与治疗达标
Microbiome-Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement
Abdelrahman Saqr, Pamala A. Jacobson*
26.一种药效计量学方法： 定量测定替尔泊肽减肥治疗中体成分改善并表征其暴露-反应关系
A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide
Emmanuel Chigutsa*
27.利用人源原代肠道3D模型推进口服药物吸收、CYP3A4诱导及转运体介导相互作用的预测
Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™)
Paresh P. Chothe*
28.通过临床药物遗传学实施联盟在全球范围内推进临床药物基因组学应用
Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Kelly E. Caudle*
29.融合外部数据的混合设计： 评估地塞米松眼内给药混悬液用于白内障术后炎症的疗效
A Hybrid Design Incorporating External Data to Evaluate Dexamethasone Intracameral Drug Delivery Suspension for Post-Cataract Surgery Inflammation
Yuanyuan Zhao*
30.甘氨鹅脱氧胆酸-3-O-硫酸酯作为OATP1B3和OAT3转运体内源性生物标志物的群体药代动力学模型研究
Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3-O-Sulfate (GCDCA-S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
Yuki Ujihira, Aleksandra Galetin*
31.中国细胞与基因治疗产品获批情况分析： 临床试验与监管进展洞察
Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances
Geyun Huang, Li Yang*
32.解锁生成式大语言模型潜力： 在出院小结中预测药物不良反应关系的分析与策略
Unlocking Potential of Generative Large Language Models for Adverse Drug Reaction Relation Prediction in Discharge Summaries: Analysis and Strategy
Yen Ling Koon, Sreemanee Raaj Dorajoo*

二、药理学评论 
Pharmacological Reviews
（本刊为双月刊，每两月更新一次，详见2026年1月更新）

三、先进药物输送评论（2025年第227卷） 
Advanced Drug Delivery Reviews
December 2025 - Volume 227 （2025年12月第227卷）

https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/227/suppl/C

Review article（综述文章）
1.用于评估药物疗效的胶质母细胞瘤-血脑屏障相互作用体外模型
In vitro models of the interplay between glioblastoma and blood–brain barrier for stratifying drug efficacy
Cecília Ferreira, Cláudia Martins*
2.闪速纳米沉淀技术二十年：从可控沉淀到全球性药物应用
20 years of Flash NanoPrecipitation – from controlled precipitation to global medicine
Kurt D. Ristroph*
3.细菌表面展示技术在药物递送中的再利用
Repurposing the bacterial surface display technology for drug delivery
Shaobo Yang, Jiahe Li*
4.黑色素细胞相关疾病基因治疗递送技术的最新进展
Recent advances in gene delivery for melanocyte-associated disorders
Tanya Chhibber, Robert L. Judson-Torres*
5.开发有效植入式给药系统的3D打印策略进展：近期应用与机遇
Advancements in 3D-printing strategies towards developing effective implantable drug delivery systems: Recent applications and opportunities
Kieran Lau*
6.用于治疗性免疫工程的一氧化氮调控生物材料
Nitric oxide-modulating biomaterials for therapeutic Immunoengineering
Yeonju Boo, Won Jong Kim*
7.用于气体疗法及气体激活型药物递送的冷大气等离子体技术
Cold atmospheric plasma for gas therapy and gas-activated drug delivery
Qiaoyun Li, Yu-Kyoung Oh*
8.肺部疾病的细胞疗法：概述与展望
Cell-based treatments of lung diseases: overview and outlook
A.M. van der Does, R. Olmer*
9.微生物组活性药物递送系统：利用微生物刺激实现药物控释
Microbiome-active drug delivery systems (MADDS): Leveraging microbial stimuli for controlled drug release
Srinivas Kamath, Paul Joyce*
10.儿科肠内饲管给药制剂的挑战——当前认知与未来方向
Paediatric formulation challenges for enteral feeding tube administration – Current understanding and future directions
Sifan Hu, Smita Salunke*
11.硫化氢在癌症治疗中的应用：智能递送平台与协同治疗新策略
Hydrogen sulfide in cancer therapy: Intelligent delivery platforms and synergistic therapeutic paradigms
Nailin Yang, Liang Cheng*
12.机器学习与人工智能在生理药代动力学建模中的应用机遇
Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling
Anne M. Talkington*
13.iPSC来源的T细胞与巨噬细胞：生产工艺与新一代应用方法
iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches
Débora Basílio-Queirós, Nico Lachmann*
14.探究人体肠道益生菌的DNA递送限制-修饰屏障以简化基因工具开发
Investigating the restriction-modification barrier to DNA delivery in human gut probiotic bacteria for streamlined genetic tool development
Qiaochu Li, Justin M. Vento*
15.渐进式科学、创新与认可之间复杂而微妙的关系
The complex and intricate relationship between incremental science, innovation and recognition
Charlotte A. Birkmanis, Dietmar W. Hutmacher*
16.病毒疫苗的组成、稳定化与递送：旨在摆脱冷链依赖的考量
Composition, stabilization and delivery of virus-based vaccines: considerations to break free of the cold chain
Amaka J. Epoh, Maria A. Croyle*
17.面向药物选择性激光烧结3D打印的进程——热学与温度依赖性分析视角
Toward pharmaceutical selective laser sintering 3D printing - a thermal and temperature-dependent analysis perspective
Marta Łaszcz, Piotr Kulinowski*
18.延长肠道滞留时间并提升结肠疾病疗效的先进粘附与靶向策略
Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases
Alita F. Miller, Juliane Nguyen*

四、药理学发展趋势 (2025年第46卷第12期)

Trends in Pharmacological Sciences
NDecember 2025 - Volume 46 - Issue 12（2025年12月第46卷第12期）
https://www.cell.com/trends/pharmacological-sciences/issue?pii=S0165-6147(25)X0012-2

Editorial（社论）
1.重塑药物发现的未来图景
Transforming the drug discovery landscape
Jerry C. Madukwe*
Science & Society（科学与社群）
2.挑战时代的药物发现韧性之路
Resilient pathways for drug discovery in challenging times
Sean Ekins*
Forum（论坛）
3.遵循CLEAR原则，确保研究方法与数据的透明度
Be CLEAR to ensure methodological and data transparency
Christopher H. George, Debbie L. Hay*
Reviews（综述）
4.荧光RNA：为药物发现开启新机遇
Fluorescent RNAs: new opportunities for drug discovery
Fangting Zuo, Yi Yang*
5基于质谱的膜蛋白药理学研究策略
Mass spectrometry-based strategies for membrane protein pharmacology
Andrew H. Reiter, Dina Schuster*
6.阐明A类GPCR中的偏向性信号转导机制
Elucidating biased signaling in class A GPCRs
Ningyang Xu, Wei Liu*
7.人工智能在抗体偶联药物研发中的应用
Artificial intelligence in antibody–drug conjugate development
Yuxi Wang*
8.迷幻药的ABC：一份药物发现的临床前路线图
The ABCs of psychedelics: a preclinical roadmap for drug discovery
Alex C. Kwan*
9.人工智能在罕见病领域的应用：走向临床影响
Artificial intelligence in rare diseases: toward clinical impact
Ana M.B. Amorim, Irina S. Moreira*
Drug of the Month（本月药物）
10.舒沃替尼（商品名：择弗罗维）：一款针对非小细胞肺癌EGFR 20号外显子插入突变的不可逆口服抑制剂
Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC
Xiaoshuang Niu, Bin Yu*

五、药理学与治疗学 (2025年第276卷)

Pharmacology & Therapeutics
December 2025 - Volume 276 （2025年12月第276卷）
https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/276/suppl/C

Editorial（社论）
1.跨越阿片危机：慢性疼痛管理的新靶点
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain
Peter Holzer*
Review article（综述文章）
2.走向融合阳性横纹肌肉瘤的定向疗法
Towards directed therapy for fusion-positive rhabdomyosarcoma
George M. Turco, Corinne M. Linardic*
3.乳腺癌患者软脑膜转移的治疗策略
Treatment strategies for leptomeningeal disease in patients with breast cancer
Lennard Spanehl, Joshua D. Bernstock*
4.疾病中抗血管生成与促血管生成通路间的交互作用：机制与治疗策略
Crosstalk between anti-angiogenic and pro-angiogenic pathways in disease: Mechanisms and therapeutic strategies
Runa Wang, Jie Ran*
5.白三烯研究中的动物模型：复杂通路与治疗干预的当前见解
Animal models in leukotriene research: Current insights into complex pathways and therapeutic intervention
Tarvi Teder, Helike Lõhelaid*

六、药物 (2025年第85卷第12期)
Drugs

December 2025 - Volume 85 - Issue 12（2025年12月第85卷第12期）
https://link.springer.com/journal/40265/volumes-and-issues/85-12

1.致谢审稿人
Acknowledgement to Referees
Current Opinion（当前观点）
2.改良型阿片类药物在急性疼痛管理中走到终点：我们如何行至此处？
The End of the Line for Modified-Release Opioids in Acute Pain Management: How Did We Get Here?
Pamela Elizabeth Macintyre*
Review Article（综述文章）
3.JAK抑制剂治疗白癜风：当前证据与新兴治疗潜力
JAK Inhibitors for the Treatment of Vitiligo: Current Evidence and Emerging Therapeutic Potential
César Ferreira, Brett King & Tiago Torres*
4.免疫检查点抑制剂的长期毒性
Long-Term Toxicities of Immune Checkpoint Inhibitors
Preethy E. Abraham, Douglas B. Johnson*
5.先天性肾上腺皮质增生症的当前治疗现状
The Current Treatment Landscape for Congenital Adrenal Hyperplasia
Joseph J. Tonge, Irina Bacila & Nils P. Krone*
6.酸性鞘磷脂酶缺乏症的当前与新兴疗法 
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency
Tamires Silva Alves, Ana Luíza Fonseca Siqueira & Roberto Giugliani*
7.基因疗法能否改变后节眼病的治疗格局？近期进展全面评述 
Can Gene Therapy Transform the Treatment Landscape of Posterior Segment Eye Diseases? A Comprehensive Review of Recent Advancements
Kai-Yang Chen, Hoi-Chun Chan & Chi-Ming Chan*
AdisInsight Report（AdisInsight 报告）
8.奥拉德韦：首次获批
Onradivir: First Approval
Arnold Lee
9.法米替尼：首次获批 
Famitinib: First Approval
Susan J. Keam
10.玛仕度肽：首次获批 
Mazdutide: First Approval
Matt Shirley
11.伊夫匹司他：首次获批 
Ifupinostat: First Approval
Simon Fung
12.利沙托克拉：首次获批 
Lisaftoclax: First Approval
Yahiya Y. Syed

七、药理学研究 (2025年第222卷)
Pharmacological Research
December 2025 - Volume 222（2025年12月第222卷）
https://www.sciencedirect.com/journal/pharmacological-research/vol/222/suppl/C

Editorial（社论）
1.高血压防治指南演进之路：聚焦2025年ACC/AHA文件
The saga of the guidelines on hypertension: Focus on the 2025 ACC/AHA document
Guido Grassi*
2.亨廷顿病中的细胞移植疗法——现状与未来方向
Cell transplantation therapies in Huntington’s disease – Current status and future directions
Angelica E. Guiloff, Roger A. Barker*
3.胰高血糖素样肽-1受体激动剂的发展历程
History of glucagon-like peptide-1 receptor agonists
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler*
Review Articles（综述文章）
4.靶向雌激素受体治疗多囊卵巢综合征：神经精神功能障碍及治疗调控的受体特异性框架
Targeting estrogen receptors in PCOS: A receptor-specific framework for neuropsychiatric dysfunction and therapeutic modulation
John Carlson*
5.獐牙菜苷：关于其生物合成、药代动力学、药理学及安全性的全面评述
Sweroside: A comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safety
Zhiqiang Gan, Yi Zhang*
6.二甲双胍对CD8⁺ T细胞的代谢调控：CD8⁺ T细胞免疫疗法的潜力辅助策略
Metabolic modulation of CD8⁺ T cells by metformin: A promising adjuvant strategy for CD8⁺ T Cell-Based Immunotherapies
Quynh Chau Ton Nu, Pil-Hoon Park*
7.葛根素对代谢功能障碍相关脂肪性肝病的保护作用及机制：动物实验的系统综述与荟萃分析
Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies
Xiang-yun Zou, Yong’an Ye*
8.癌症中脂滴与自噬的交互作用：治疗靶向的关键节点
Crosstalk between lipid droplets and autophagy in cancer: A nexus for therapeutic targeting
Xiaofen Li, Chuangui Song*
9.经典与下一代大麻素配体的研发及治疗潜力
The development and therapeutic potential of classical and next-generation cannabinoid ligands
Verónica Muñoz-Canales, Silvia Ortega-Gutiérrez*
10.中药通过调节肠道菌群在癌症免疫治疗中的应用：现状、机制、挑战与展望
Applications of traditional Chinese medicine in cancer immunotherapy via gut microbiota modulation: Current status, mechanisms, challenges and perspectives
Heyun Tao, Xuefei Tian*
11.饮食、肠-脑轴与代谢-表观基因组-免疫网络：神经系统疾病管理的三位一体
Diet, gut-brain axis, and metabolism-epigenome-immunity networks: A triad in neurological disease management
Yishu Fan, Xiaoyuan Mao*
12.HFpEF中的糖代谢性心功能不全：多组学研究带来的启示
Glycometabolic cardiac dysfunction in HFpEF: Lessons from multi-omics studies
Susanna Longo, Massimo Federici*
13.GLP-1受体激动剂的精神调节作用
Psychotropic effects of GLP-1R agonists
Loredana Bucciarelli, Paolo Fiorina*
14.自闭症谱系障碍中的喂养困难、进食障碍及治疗途径概述
Feeding difficulties, eating disorders and therapeutic approaches in autism spectrum disorder: An overview
Martina Siracusano, Sergio Davinelli*
15.骨关节炎中的适应性免疫：调节性T细胞靶向治疗的机制与机遇
Adaptive immunity in osteoarthritis: Mechanisms and opportunities for regulatory T-cell–targeted therapy
Xueyou Zhang, Patrick Shu-Hang Yung*
16.花青素纳米递送系统在抗炎治疗中的研究进展
Advances in anthocyanin nanoparticle delivery systems in anti-inflammatory therapies
Hanchi Zhang, Yiming Gan*
17.SGLT2抑制剂的广泛作用：聚焦于巨噬细胞介导的效应
Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action
Bing Shu, Chengxiao Fu*
18.中药通过靶向非编码RNA克服癌症耐药性的作用：机制与临床转化挑战
The role of Chinese medicines in targeting non-coding RNAs to overcome cancer drug resistance: Mechanisms and clinical translation challenges
Guoming Chen, Yibin Feng*
19.内溶酶体作为新兴病毒的“分拣中心”：细胞防御与病毒命运的门卫及其治疗靶点潜力
Endolysosomes as a sorting hub for emerging viruses: Gatekeepers of cellular defense, viral fate and promising therapeutic target
Sophie Post, Lena Rueschpler, Sebastian Schloer*
20.细胞的ARK面：激酶、代谢及其在恶性肿瘤中的治疗潜力
The ARK side of the cell: Kinases, metabolism, and therapeutic potential in malignancies
Viviana Coliboro-Dannich, Ariel Fernando Castro*
21.从燃料到表观遗传信号：乳酸-乳酸化轴调控糖尿病并发症
From fuel to epigenetic signal: Lactate-lactylation axis orchestrates diabetic complications
Siyu Guo, Chen Liu*
22.靶向蛋白酶体降解嵌合体技术靶向降解假激酶以治疗MASH及纤维化：机制与治疗启示
Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights
Yibing Wang*
23.已获批用于癌症治疗的聚腺苷二磷酸核糖聚合酶抑制剂
Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer
Robert Roskoski*
24.SLC转运体作为肿瘤发生中铁死亡的“守门人”：从分子机制到临床潜力
SLC transporters as metalloptotic gatekeepers in tumorigenesis: From molecular mechanisms to clinical potential
Bingchen Pan, Liping Sun*
25.从肠道到大脑：靶向5-羟色胺能通路治疗炎症性肠病的潜在新途径
From the gut to the brain: Potential novel avenues for IBD treatment via serotonergic pathways
Sara Ibgui, Daisy Lints, Simon Milling*
Regular Articles（研究文章）
26.独活寄生汤通过抑制eEF2K介导的细胞衰老减轻绝经后类风湿关节炎
Duhuo Jisheng Decoction mitigates postmenopausal rheumatoid arthritis by suppressing eEF2K-mediated cellular senescence
Danli Chen, Hudan Pan*
27.靶向内源性/旁系大麻素系统治疗暴食行为：双配体在临床前模型中的疗效
Targeting the endocannabinoid/paracannabinoid systems in binge eating behavior: Efficacy of dual ligands in a preclinical model
Marialuisa de Ceglia, Fernando Rodriguez de Fonseca*
28.探究青藤碱与不同DNA片段的嵌入功效以理解其对DNA甲基化水平的调节作用
Investigating the intercalation efficacy of sinomenine with diverse DNA fragments to understand its regulatory role in DNA methylation levels
Yun-Da Yao, Hua Zhou*
29.靶向细胞衰老可改善DMD/Utrophin双敲除小鼠的骨骼肌健康并延长其寿命
Targeting cellular senescence in dystrophin-/-/utrophin-/-double knockout mice improves musculoskeletal health and increases lifespan
Xueqin Gao
30.大麻二酚与β-石竹烯在慢性炎性疼痛中的作用
Cannabidiol and Beta-Caryophyllene: Chronic inflammatory pain
Mohammed Alnoud, Khalid Benamar*
31.基于一种长效易递送的TNF-α衍生肽鉴定有效的肝纤维化治疗方法
Identification of an effective treatment for liver fibrosis based on a long acting easy to deliver TNF-α-derived peptide
Xiaowen Qiu, Haifeng Liu*
32.短异戊二烯重复萜类对Cx43间隙连接的选择性高于心脏Na⁺与Ca²⁺通道：在心脏神经传导研究中的应用
Preference of short isoprene-repeat terpenes for Cx43 gap junctions compared with cardiac Na+ and Ca2+ channels: application for cardiac ephaptic transmission research
Vytautas Raškevičius, Vytenis Arvydas Skeberdis*
33.乳香（Pistacia lentiscus var. Chia）疗法治疗功能性消化不良的随机三交叉临床试验
A randomized, three-way crossover clinical trial on the efficacy of Mastiha based therapies (Pistacia lentiscus var. Chia) in functional dyspepsia
Stamatia-Angeliki Kleftaki, Andriana C. Kaliora*
34.Mdivi-1促进脂滴-线粒体接触并改善高脂饮食喂养小鼠的心脏脂毒性
Mdivi-1 promotes lipid droplets-mitochondria contact and ameliorates cardiac lipotoxicity in high-fat diet-fed mice
Zujie Xu*
35.内质网应激感受器PERK通过破坏线粒体相关膜介导的线粒体稳态并促进mtROS积累驱动急性心肌梗死的铁死亡
ER stress sensor PERK drives ferroptosis by disrupting MAMs-mediated mitochondrial homeostasis and promoting mtROS accumulation in acute myocardial infarction
Xueshu Tao, Zhipeng Cao*
36.用于评估临床GPCR激动剂偏向性信号转导的动力学多重测定法
Kinetic multiplex assay to assess biased signaling of clinical GPCR agonists
Jara Bouma, Laura H. Heitman*
37.KRAS信号再激活稳定CDC7从而损害KRAS突变型结直肠癌的化疗敏感性
CDC7 stabilized by KRAS signaling reactivation impairs chemosensitivity in KRAS-mutant colorectal cancer
Ruilin Wu, Hong Zhu*
38.何首乌植物来源的外泌体样纳米颗粒通过miRNA递送介导跨界作用并调节雄激素通路促进毛发生长
Cross-kingdom delivery and putative gene modulation of androgen pathways by plant-derived exosome-like nanoparticles from polygoni multiflori radix promotes hair growth via miRNA cargo
Shaojin Li, Liqin Zhang*
39.Parishin A通过肠道菌群提高肠道EAAT3活性以降低血氨从而减轻肝性脑病
Parishin A reduces hepatic encephalopathy via gut microbiota increasing the activity of intestinal EAAT3 to reduce blood ammonia
Jin-Yue Lu, Yan Wang*
40.负载DACHPt的生物材料纳米颗粒在结直肠癌腹膜转移中的免疫调节腹腔化疗
Immunomodulatory intraperitoneal chemotherapy with DACHPt-loaded biomaterial nanoparticles in colorectal carcinomatosis
Giuseppina Catania, Giovanna Lollo*
41.吡唑啉酮类ERO1抑制剂在ERO1驱动型三阴性乳腺癌与SEPN1相关肌病中的应用：构效关系与治疗潜力
Pyrazolone-based ERO1 inhibitors in ERO1-driven triple-negative breast cancer and SEPN1-related myopathy: Structure–activity relationship and therapeutic potential
Michele Retini, Ester Zito*
42.吴茱萸碱通过诱导小胶质细胞PANoptosis减轻重型创伤性脑损伤后的神经功能缺损
Evodiamine attenuates neurological impairment by inducing PANoptosis in microglia after severe traumatic brain injury
Huiqin Zheng, Xiaofeng Yang*
43.PXR激活可通过NRF2信号通路改善高尿酸血症肾病
PXR activation ameliorates hyperuricemic nephropathy via NRF2 signaling
Ting Wu, Huichang Bi*
44.一种广谱抗血管生成四肽通过与β- arrestin-1结合及抑制Akt磷酸化消退糖尿病视网膜病变
A broad-spectrum anti-angiogenic tetrapeptide regresses diabetic retinopathy through β-arrestin-1 binding and prevention of Akt phosphorylation
Alberto Zani, Arnaldo Caruso*
45.源自T细胞活化相关免疫基因的泛癌预后特征：侧重于乳腺癌在内的恶性肿瘤的实验验证
A clinically relevant pan-cancer prognostic signature derived from T-cell activation immune genes: Experimental validation across malignancies with emphasis on breast cancer
Jia-Ning Zhang, Hong Liu*
46.艾司氯胺酮对心脏瓣膜手术患者术后抑郁及焦虑的影响：一项随机、安慰剂对照、双盲临床试验
Effect of esketamine on postoperative depression and anxiety in patients undergoing cardiac valve surgery: A randomised, placebo-controlled, double-blinded clinical trial
Zhuo-Ning Zhang, Li Tong*
47.人参皂苷Re跨物种结合Drp1 Leu94，通过Atg1/ULK1依赖的分裂-自噬耦联恢复线粒体稳态，改善年龄相关性退行性病变
Ginsenoside Re binds Drp1 Leu94 across species to restore mitochondrial homeostasis via Atg1/ULK1-dependent fission-mitophagy coupling in age-related degeneration
Chenrong Jin, Meichen Liu*
48.空间蛋白质组学分析揭示小细胞肺癌不同分子亚型中保守的预后免疫微环境特征
Spatial proteomic profiling reveals conserved prognostic immune microenvironment features across molecular subtypes in small cell lung cancer
Modi Zhai, Lin Yang*
49.Mesinostat选择性抑制HDAC6损害三阴性乳腺癌的肿瘤生长与干性
Selective HDAC6 inhibition by Mesinostat impairs tumor growth and stemness in triple-negative breast cancer
Ivana Bello, Elisabetta Panza*
50.通过鞘磷脂驱动的TRPML1失活及靶向溶酶体HSP70抑制TFEB，克服ELDR介导的癌细胞体外与体内生存
Overcoming ELDR-mediated cancer cell survival in vitro and in vivo via sphingomyelin-driven TRPML1 inactivation and TFEB suppression through lysosomal HSP70 targeting
Hongyu Chen, Hui Hui*
51.靶向单羧酸转运蛋白MCT4是治疗转移性透明细胞肾细胞癌的新策略
Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCC
Lena-Sophie Menig-Benzig, Matthias Schwab*
Letters to the Editor（致编辑的信）
52.在GLP-1受体激动剂治疗患者的临床监测中整合基于基因型的随访算法以降低胰腺炎风险
Integrating a genotype-based follow-up algorithm in clinical surveillance to mitigate the risk of pancreatitis in patients treated with GLP-1R agonists
Angeliki Margoni, Athanasios G. Papavassiliou*

八、抗病毒研究 (2025年第243卷)
Antiviral Research
December 2025 - Volume 244（2025年12月第244卷）
https://www.sciencedirect.com/journal/antiviral-research/vol/244/suppl/C

Research article（研究文章）
1.口蹄疫病毒复制复合体的组成、三维结构及其形成机制
Composition, three-dimensional structure and formation mechanism of the foot and mouth disease virus replication complexes
Bonan Lv, Chao Shen*
2.环吡酮通过靶向铁代谢抑制痘病毒复制
Ciclopirox suppresses poxvirus replication by targeting iron metabolism
Anil Pant, Zhilong Yang*
3.解析来特莫韦的作用模式与耐药突变效应
Deciphering letermovir's mode of action and resistance mutation effects
C. Gourin, S. Hantz*
4.支持布林西多福韦依据美国FDA动物规则获批的关键动物疗效研究
Pivotal animal efficacy studies supporting brincidofovir licensure under the FDA animal rule
Daniel C. Sanford, Shantha Kodihalli*
5.基线病毒准种特征与演化阶段与聚乙二醇干扰素-α-2a治疗的HBeAg阳性慢性乙型肝炎患儿HBsAg血清学转换相关
Pretreatment viral quasispecies characteristics and evolutionary phases correlate with HBsAg seroconversion in peginterferon-alfa-2a-treated children with HBeAg-positive chronic hepatitis B
Juncheng Yang, Zhihua Liu*
6.抗病毒药物敏感性监测：2023-2024流感季的检测流程、方法与发现
Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023–2024
Mira C. Patel, Larisa V. Gubareva*
7.嘧啶合成抑制剂与N4-羟基胞苷协同作用以抑制流感病毒复制
Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication
Leon Schrell, Matthias Dobbelstein*
8.解析1′、2′及4′位核苷酸修饰对呼吸道合胞病毒RNA依赖性RNA聚合酶的影响
Mapping the impact of 1′-, 2′- and 4′-nucleotide modifications on the Respiratory Syncytial Virus RNA-dependent RNA polymerase
Priscila Sutto-Ortiz, Etienne Decroly*
9.人工蛋白（αReps）通过靶向RNA聚合酶抑制流感病毒复制
Inhibition of influenza virus replication by artificial proteins (αReps) targeting its RNA-polymerase
Mélissa Bessonne, Bernard Delmas*
10.SUCLG2在硝唑尼特抗日本脑炎病毒活性中起关键作用
SUCLG2 plays a crucial role in the activity of Nitazoxanide against Japanese encephalitis virus
Min Wei, Keyu Zhang*
11.通过腺病毒载体转导携带人IGF1受体的条件性基因敲入小鼠快速构建小鼠呼吸道合胞病毒感染模型
Rapid generation of a murine RSV infectious model by transducing a conditional knock-in mouse harboring human IGF1 receptor with adenoviral vector
Rui Xiong, Yihong Peng*
12.设计、合成及生物学评价：一系列具有抗呼吸道合胞病毒活性的新型N1-（膦酰烷基）-1,2,3-三唑与N3-苄基-6-溴喹唑啉-2,4-二酮偶联物
Design, synthesis and biological evaluation of a novel series of conjugates of N1-(phosphonoalkyl)-1,2,3-triazoles and N3-benzyl-6-bromoquinazoline-2,4-diones with anti-RSV activity
Iwona E. Głowacka*
13.用于冠状病毒生物学及对策开发的双报告基因HCoV-OC43病毒模型
A dual-reporter HCoV-OC43 for coronavirus biology and countermeasure development
Xiangxue Deng, Xuping Xie*
14.老药新用：度硫平靶向宿主AXL激酶破坏柯萨奇病毒B感染中病毒2C蛋白介导的免疫逃逸
Repurposed doxepin targeting host AXL kinase to disrupt viral 2C-mediated immune evasion in Coxsackievirus B infection
Ran Yan, Qinchang Zhu*
15.全基因组CRISPR筛选揭示抗病毒药物疗效的遗传决定因素
Genetic determinants of efficacy of antiviral drugs revealed by genome-wide CRISPR screens
Wei Jiang, Hai Jiang*
16.天然多酚原花青素A2通过干扰复制早期阶段预防埃博拉病毒和狂犬病病毒的体外感染
The natural polyphenol proanthocyanidin A2 prevents the in vitro infection of Ebola virus and rabies virus by interfering with the early phases of the replication cycle
Denis Pasqual, Cristiano Salata*
Short communication（简短通讯）
17.冻干技术实现登革病毒来源缺陷干扰颗粒的热稳定制剂开发
Lyophilization enables thermostable formulation of dengue virus-derived defective interfering particles
Min-Hsuan Lin, David Harrich*
Review article（综述文章）
18.乙型肝炎病毒DNA整合的生物学特性及其对抗病毒研发的影响
Biology of hepatitis B virus DNA integration and its impact on antiviral R&D
Lottida Phondeth, Thomas Tu*
19.小分子HBV RNA去稳定剂：未来药物还是昔日的化合物？
Small molecule HBV RNA destabilizing drugs: Drugs of the future or compounds from the past?
Timothy M. Block*

九、英国药理学杂志 (2025年第182卷第23-24期)
British Journal of Pharmacology
（一）December 2025 - Volume 182 - Issue 23（2025年12月第182卷第23期）
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2025/182/23

REVIEW ARTICLE（综述文章）
1.HCN4离子通道异常表达：对神经元兴奋性的影响及其在癫痫发病机制中的意义
Aberrant HCN4 channel expression: Impacts on neuronal excitability and implications for epilepsy pathogenesis
James Spyrou, Christopher A. Reid*
INVITED REVIEW（特邀综述）
2.肺动脉高压中的炎症消退与性别影响——国际基础与临床药理学联合会免疫药理学委员会综述
Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review
Chloe Landy, Cheng Xue Qin*
BIOINFORMATIC TOOL（生物信息学工具）
3.通路水平突变特征预测乳腺癌预后并揭示治疗靶点
Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets
Máté Posta, Balázs Győrffy*
RESEARCH ARTICLE（研究论文）
4.氯离子通道对分娩期人类子宫肌层动作电位及收缩的贡献
Contribution of chloride channels to the action potential and contraction in human myometrium during labour
Helena C. Parkington*
5.短链脂肪酸通过调节T细胞异质性缓解复发性自然流产
Short-chain fatty acids regulate T cell heterogeneity to alleviate recurrent spontaneous abortion
Yao Yao, Caihong Zheng*
6.伴有阻塞性睡眠呼吸暂停的哮喘患者对皮质类固醇不敏感：氧化应激与组蛋白乙酰化的作用
Corticosteroid insensitivity in asthma associated with obstructive sleep apnoea: Role of oxidative stress and histone acetylation
Chun-Yu Lo*
7.与他汀类药物相关的2型糖尿病遗传变异：来自英国生物样本库与“全民研究计划”的发现
Genetic variants linked to statin-associated Type 2 diabetes mellitus: Findings from the UK Biobank and the All of Us Research Program
Yoon-A Park, Hye Sun Gwak*
8.TRPA1离子通道激活在正常与银屑病人体皮肤中依赖情境调控基因表达
TRPA1 ion channel activation context-dependently regulates gene expression in normal and psoriatic human skin
Ágnes Kemény*
9.褐煤酸（一种FFAR4激动剂）被鉴定为电压门控钠通道与CaV2.2通道的双重拮抗剂，具有强效镇痛作用
Grifolic acid, a FFAR4 agonist, identified as a dual antagonist of voltage-gated sodium and CaV2.2 channels with potent antinociceptive effects
Miao Zhao, Haibo Yu*
10.β-榄香烯通过靶向PPARα改善实验性饮食诱导的代谢功能障碍相关脂肪性肝炎
β-elemene ameliorates metabolic dysfunction-associated steatohepatitis by targeting PPARα in experimental diet-induced models
Yongqiang Xiong, Weiwei Zhu*
11.一种新型α5-GABA_A受体抑制剂的合成与评估用于治疗周围神经痛：来自分子动力学模拟与体内研究的证据
Synthesis and evaluation of a novel inhibitor for the α5-GABAA receptor in the treatment of peripheral neuralgia: Evidence from MD simulation and in vivo studies
Yanming Chen, Zhenming Liu*
12.阿片类部分激动剂PPL-138降低易患创伤后应激障碍的大鼠的酒精自我给药行为
The opioid partial agonist PPL-138 reduces alcohol self-administration in rats susceptible to post-traumatic stress disorder
Andrea Cippitelli*
13.胆红素通过抑制芳烃受体介导的腺泡细胞焦亡预防高脂血症性急性胰腺炎
Bilirubin prevents hyperlipidaemic acute pancreatitis by inhibiting aryl hydrocarbon receptor-mediated acinar cell pyroptosis
Wenjie Liang, Jun Yang*
14.GCN2调控紫杉醇诱导的神经病理性疼痛
GCN2 regulates paclitaxel-induced neuropathic pain
Alexander R. Mikesell, Zachary T. Campbell*

（二）December 2025 - Volume 182 - Issue 24 （2025年12月第182卷第24期）

https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2025/182/24

RESEARCH ARTICLE（研究文章）
1.黄芪甲苷通过抑制RELM-β减少PINK1/Parkin介导的线粒体自噬，缓解低氧性肺动脉高压
Astragaloside IV alleviates hypoxic pulmonary hypertension by inhibiting RELM-β to reduce PINK1/Parkin-mediated mitophagy in pulmonary artery smooth muscle cells (PASMCs)
Rongzhen Ding, Aiguo Dai*
2.抑制钙调磷酸酶/FoxO1/脂肪酸结合蛋白4通路可防止SERCA2功能障碍诱导的泡沫细胞形成与动脉粥样硬化
Inhibition of the calcineurin/forkhead box O1/fatty acid binding protein 4 pathway prevents SERCA2 dysfunction-induced foam cell formation and atherosclerosis
Beibei Zhu, Pingping Hu*
3.激活Sigma-1非阿片类细胞内受体通过抑制AIM2驱动的炎症反应改善脑卒中后认知障碍
Sigma non-opioid intracellular receptor 1 activation relieves post-stroke cognitive impairment via suppressing AIM2-driven inflammatory response
Hui Ma, Yun-Feng Li*
4.肽类药物CIGB-552与依列沙福/替扎沙福/依伐卡福三联疗法联用对CFTR-F508del突变具有协同增效作用
Peptide CIGB-552 has a synergistic effect on CFTR-F508del when combined with elexacaftor/tezacaftor/ivacaftor triple therapy for cystic fibrosis
Benjamin Simonneau, Abdel Aissat*
5.HMC通过去泛素化并稳定ATP7A蛋白抑制铜死亡，减轻心肌缺血-再灌注损伤
HMC ameliorates myocardial ischaemia–reperfusion injury through suppressing cuproptosis via the de-ubiquitination and stabilization of ATP7A
Jia-Bao Su, Hai-Jian Sun*
6.磷脂酰肌醇-4,5-二磷酸3-激酶抑制剂在体外和体内实验中减轻血管炎症
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitors reduce vascular inflammation in vitro and in vivo
Hiba Chaudhry, Susan D. Brain*
7.利用福斯高林依赖与非依赖PP2A的效应靶向治疗KMT2A重排急性白血病
Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemia
Yoana Arroyo-Berdugo, Maria Teresa Esposito*
8.对位于第四胞内环的囊性纤维化跨膜电导调节器致病突变进行计算机、体外及离体表征，并评估调节剂的挽救效果
In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators
Emanuela Pesce, Nicoletta Pedemonte*
9.阐明锌离子在KCNQ通道中的结合位点
Elucidation of the zinc binding site in KCNQ channels
Shuo Zhang, Haixia Gao*
10.E3泛素连接酶Pellino1通过促进泛素依赖性RIP3降解抑制腺泡细胞坏死性凋亡并缓解重症急性胰腺炎
E3 ubiquitin ligase Pellino1 suppresses acinar cell necroptosis and alleviates severe acute pancreatitis by promoting ubiquitin-dependent receptor-interacting protein kinase 3 (RIP3) degradation
Jiatong Chen, Peng Tan*
11.血管紧张素II诱导的CHK1丝氨酸-280磷酸化通过直接磷酸化JAK1驱动心脏重构，从而激活小鼠心肌细胞中的JAK1-STAT信号通路
Angiotensin II-induced phosphorylation of CHK1 at serine-280 drives cardiac remodelling by direct phosphorylation of JAK1, thus activating JAK1-STAT signalling in murine cardiomyocytes
Zheng Xu, Guang Liang*
12.一种兼具μ-阿片受体与神经肽FF受体激动活性的新型芬太尼-肽偶联物在雄性小鼠中产生镇痛作用且副作用有限
A novel peptide-fentanyl conjugate with μ-opioid and neuropeptide FF receptor agonism produces antinociception with limited side effects in male mice
Ning Li, Quan Fang*

十、临床药代动力学 (2025年第64卷第12期)
Clinical Pharmacokinetics
December 2025 -Volume 64 - Issue 12（2025年12月第64卷第12期）
https://link.springer.com/journal/40262/volumes-and-issues/64-12

1.致谢审稿人
Acknowledgement to Referees
Review Article（综述文章）
2.药物干预策略降低肾病患者血清对甲酚硫酸盐的临床药代动力学-药效学关系
Clinical Pharmacokinetic-Pharmacodynamic Relationships of Pharmacological Strategies for Attenuating p-Cresyl Sulfate in Patients with Kidney Disease
Puja Dhungana, Andrew Dam & Tony K. L. Kiang*
Original Research Article（原创研究论文）
3.Efsubaglutide Alfa在2型糖尿病患者中的暴露-反应分析 
Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
Qinghua Wang*
4.Efsubaglutide Alfa在经二甲双胍治疗的2型糖尿病患者中的暴露-反应分析
Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin
Qinghua Wang*
5.新生儿芬太尼相关不良事件与药代动力学评估：基于生理的药代动力学建模方法 
Evaluation of Fentanyl-Emerged Adverse Events and Pharmacokinetics in Neonates: A Physiologically Based Pharmacokinetic Modeling Approach
Walaa Yousef Bassyouni Mahdy, Kazuhiro Yamamoto*
6.基于生理的药代动力学模型预测氨苄西林/舒巴坦预防性给药在下颌骨坏死患者血浆与骨组织中的暴露量
A Physiologically Based Pharmacokinetic Model for the Prediction of Plasma and Bone Tissue Exposure after Prophylactic Administration of Ampicillin/Sulbactam in Patients with Osteonecrosis of the Jaw
Maximilian Stapf, Oliver Scherf-Clavel*
7.结合人体离体胎盘灌注数据与基于生理的药代动力学模型预测母胎对艾司西酞普兰、舍曲林及帕罗西汀的暴露水平
Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling
Laure-Hélène Préta*
8.溶酶体捕获与疟原虫感染对咯萘啶药代动力学的影响：基于生理药代动力学模型的研究
Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study
Wan-Yu Chu, Thomas P. C. Dorlo*
9.气道黏液中药物空间分布的动力学与药效学建模
Spatial Pharmacokinetic and Pharmacodynamic Modeling in Airway Mucus
Yuchen Guo, J. G. Coen van Hasselt*
10.儿童剂量桥接研究：悬混剂型利福喷丁与异烟肼在成人结核病预防性治疗中的相对生物利用度随机开放试验
Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
Saskia Janssen*
11.Olorigliflozin在伴有或不伴肾功能损害的2型糖尿病患者中的药代动力学、药效学与安全性评估：单中心、单剂量、开放标签试验
Pharmacokinetics, Pharmacodynamics, and Safety of Olorigliflozin in Individuals with Type 2 Diabetes Mellitus with or without Renal Impairment: A Single-Center, Single-Dose, Open-Label Trial
Man Chen, Ping Feng